Abstract: A pharmaceutical preparation comprising a hydrophilic gel-forming agent, water and a compound of the formula I is suitable for the treatment and prophylaxis of dermatomycoses.
Type:
Grant
Filed:
September 16, 1997
Date of Patent:
March 28, 2006
Assignee:
Aventis Pharma Deutschland GmbH
Inventors:
Manfred Bohn, Karl Theodor Kraemer, Astrid Markus
Abstract: Substituted benzothiepine 1,1-dioxide derivatives of formula I: in which R1, R2, R3, R4, R5 and Z have the meanings indicated, and their physiologically tolerable salts and physiologically functional derivatives and a process for their preparation are described. The compounds are suitable, for example, as hypolipidemics.
Abstract: The invention relates to compounds of the formula (I) process for their preparation starting from the plant Beilschmiedia fulva, PLA 101037, and the use thereof for producing a medicament, in particular for the treatment of allergic disorders, of asthmatic disorders, of inflammatory concomitant symptoms of asthma and/or of diseases which can be treated by inhibiting c-maf and NFAT.
Type:
Grant
Filed:
July 25, 2003
Date of Patent:
March 28, 2006
Assignees:
Aventis Pharma Deutschland GmbH, Aventis Pharmaceuticals Inc.
Inventors:
Claudia Eder, Herbert Kogler, Sabine Haag-Richter
Abstract: Embodiments of the invention relate to C2-substituted indan-1-ols and to their physiologically acceptable salts and physiologically functional derivatives. Compounds of embodiments of the invention may include compounds of formula I in which the radicals are as defined, and their physiologically acceptable salts and processes for their preparation. The compounds are suitable, for example, for use as anorectics.
Type:
Grant
Filed:
November 4, 2004
Date of Patent:
March 21, 2006
Assignee:
Aventis Pharma Deutschland GmbH
Inventors:
Gerhard Jaehne, Volker Krone, Martin Bickel, Matthias Gossel
Abstract: The use of triaryl acid derivatives of formula (I) and their pharmaceutical compositions as PPAR ligand receptor binders. The PPAR ligand receptor binders of this invention are useful as agonists or antagonists of the PPAR receptor.
Type:
Grant
Filed:
November 28, 2000
Date of Patent:
February 28, 2006
Assignee:
Aventis Pharma Deutschland GmbH
Inventors:
Zaid Jayyosi, Gerard M. McGeehan, Michael F. Kelley, Richard F. Labaudiniere, Litao Zhang, Robert D. Groneberg, Daniel G. McGarry, Thomas J. Caulfield, Anne Minnich, Mark Bobko, Robert Morris
Abstract: Compounds of the formula I, in which R1, R2, R3, R4, R5, and R6 have the meanings given in the description, and their physiologically acceptable salts. The compounds are suitable for use, for example, as hypolipidemics.
Type:
Grant
Filed:
December 19, 2001
Date of Patent:
January 31, 2006
Assignee:
Aventis Pharma Deutschland GmbH
Inventors:
Heiner Glombik, Werner Krame, Stefanie Flohr, Wendelin Frick, Hubert Heuer, Gerhard Jaehne, Andreas Lindenschmidt, Hans-Ludwig Schäfer
Abstract: Modified oligonucleotides which possess at least one substituted 7-deazapurine base form more stable hybridization complexes with nucleic acids than unsubstituted analogs. They are useful as inhibitors of gene expression, as probes for detecting nucleic acids, as aids in molecular biology and as pharmaceuticals or diagnostic agents. Processes for preparing them are provided.
Abstract: The invention relates to p-thienylbenzylamides of formula (I): in which R(1), R(2), R(3), R(4), R(5), R(6) and X have the meanings given in the description. The compounds of formula (I) are potent agonists of angiotensin-(1-7) receptors and are useful as pharmaceutically active compounds to treat and/or prevent hypertension; cardiac hypertrophy; cardiac insufficiency; coronary heart diseases, such as angina pectoris; and endothelial dysfunction or endothelial damage as a consequence, for example, of atherosclerotic processes or in association with diabetes mellitus.
Abstract: The present invention is directed to C2-disubstituted indan-1-ol systems of the Formula I, physiologically acceptable salts and physiologically functional derivatives thereof, and pharmaceutical compositions comprising such compounds, salts, and derivatives, which are useful for reducing weight, for the prophylaxis or treatment of obesity, and for the prophylaxis or treatment of type II diabetes in mammals. The invention is directed also to methods for reducing weight and such treatments and prophylaxis. The invention is directed also to processes for the preparation of such compounds.
Type:
Grant
Filed:
August 29, 2002
Date of Patent:
January 3, 2006
Assignee:
Aventis Pharma Deutschland GmbH
Inventors:
Gerhard Jaehne, Volker Krone, Martin Bickel, Matthias G ssel
Abstract: The present invention provides a process for identifying substances that modulate the activity of hyperpolarization-activated cation channels, and the use of this process.
Type:
Grant
Filed:
February 7, 2002
Date of Patent:
December 27, 2005
Assignee:
Aventis Pharma Deutschland GmbH
Inventors:
Hans-Willi Jansen, Andrea Brüggemann, Holger Heitsch, Heinz Gögelein
Abstract: Compounds of the formula I are suitable for preparing pharmaceuticals for the prophylaxis and therapy of disorders in whose course an increased activity of NF?B is involved.
Type:
Application
Filed:
July 22, 2005
Publication date:
December 22, 2005
Applicant:
AVENTIS PHARMA DEUTSCHLAND GMBH
Inventors:
Olaf Ritzeler, Hans Stilz, Bernhard Neises, Gerhard Jaehne, Joerg Habermann
Abstract: The present invention provides various processes for the preparation of (R)-?-(2,3-dimethoxyphenyl)-1-[2-(4-fluorophenyl)ethyl]-4-piperidinemethanol.
Type:
Application
Filed:
April 26, 2005
Publication date:
November 24, 2005
Applicants:
Aventis Pharmaceuticals Inc., Aventis Pharma Deutschland GmbH
Inventors:
Wolfgang Laux, Gerard Guillamot, Frederick Laskovics, Chi-Hsin King, James Hitt, Sandra Stolz-Dunn, Ian Tomlinson, Johannes Koek
Abstract: The invention relates to a widely applicable process for identifying chemical compounds, which modulate G-protein-coupled receptors, by means of novel hybrid G-proteins with broad receptor specificity and very high expression and also to chemical compounds which can be identified by such a process.
Abstract: A preparation comprising a compound which essentially prevents the enterohepatic circulation of nucleotide synthesis inhibitors or antagonizes the action of the nucleotide synthesis inhibitors with a displacement in time, and a nucleotide synthesis inhibitor such as brequinar, mycophenolatemofetil (2-morpholinoethyl (E)-6-(1,3-dihydro-4-hydroxy-6-methoxy-7-methyl-3-oxoisobenzofuran-5-yl)-4-methyl-4-hexenoate), methotrexate, mizoribine and compounds of formulae (I) and (II) is suitable for the treatment of immunological disorders, cancer, or in transplantations.
Abstract: The invention relates to new methods and compositions for treating diabetics, pre-diabetics, and patients at risk of becoming diabetic or with impaired glucose tolerance. The invention, in one embodiment, involves activating insulin receptor substrate-2 to protect against loss of beta cell mass, protect against loss of beta cell function, rejuvenate beta cells mass, rejuvenate beta cell function or any combination thereof, thereby stimulate insulin production using an effective amount of LysB3,GluB29 insulin to patients in need of this treatment.
Type:
Application
Filed:
July 11, 2005
Publication date:
November 10, 2005
Applicant:
Aventis Pharma Deutschland GmbH
Inventors:
Gerhard Seipke, Irini Rakatzi, Olaf Dransfeld, Jurgen Eckel
Abstract: The present invention relates to compounds of the formula (I) which are formed by the microorganism ST 003236 (DSM 14476) during fermentation, to a process for preparing and derivatizing them, to a pharmaceutical which comprises a compound of the formula (I) and to the use thereof for producing a pharmaceutical.
Type:
Grant
Filed:
November 8, 2002
Date of Patent:
November 8, 2005
Assignee:
Aventis Pharma Deutschland GmbH
Inventors:
Matthias Schiell, Martin Knauf, Luigi Toti, Astrid Markus-Erb
Abstract: The present invention relates to novel imidazolidine derivatives of the formula I, in which B, E, W, Y, R, R2, R3, R30, e and h have the meanings given herein. The compounds of the formula I are valuable pharmaceutically active compounds which are suitable, for example, for treating inflammatory diseases, for example, rheumatoid arthritis, or allergic diseases. The compounds of the formula I are inhibitors of the adhesion and migration of leukocytes and/or antagonists of the adhesion receptor VLA-4, which belongs to the integrin group. They are generally suitable for treating diseases which are caused by, or associated with, an undesirable degree of leukocyte adhesion and/or leukocyte migration or in which cell-cell or cell-matrix interactions, which are based on the interactions of VLA-4 receptors with their ligands, play a role.
Abstract: The invention relates to a formulation comprising a polypeptide selected from at least one of insulin, an insulin metabolite, an insulin analog, and an insulin derivative; at least one surfactant; optionally at least one preservative; and optionally at least one of an isotonicizing agent, a buffer or an excipient, wherein the formulation is free from or low in zinc. The invention also relates to the production of such insulin preparations and their use as pharmaceutical formulations.
Abstract: The invention relates to the use of compounds of formula I for the production of a medicament for the treatment of illnesses which can be influenced by inhibition of the Na+/H+ exchanger, and to a medicament comprising them. in which R1 to R9 have the meanings shown in the claims.
Type:
Grant
Filed:
May 20, 2003
Date of Patent:
October 25, 2005
Assignee:
Aventis Pharma Deutschland GmbH
Inventors:
Armin Hofmeister, Uwe Heinelt, Hans-Jochen Lang, Markus Bleich, Klaus Wirth, Michael Gekle